 |
Acorda Therapeutics reported positive results following a 14 week phase III clinical trial with a slow release tablet form of 4-aminopyridine (drug name: Fampridine-SR). The drug is thought to improve the conduction of nerve impulses, even if the nerve fibres' insulating coat of myelin has been damaged as a result of MS.
The company reported that 35 percent of people responded to the treatment, showing an average increase of 25 percent in their walking speed compared to those on placebo. Another positive outcome was increased leg strength in those on active treatment. People that responded to the drug, also reported feeling "less disabled" in daily activities requiring mobility.
To read more, please click on the link below.
Source: UK MS Society
Weblink: click here
|
